Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Gastroenterology,Hepatology
Link
http://www.nature.com/articles/ajg20171.pdf
Reference4 articles.
1. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features.;Calderaro;Hepatology,2016
2. Kinase inhibitor sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.;Cao;Lab Invest,2011
3. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.;Chen;Int J Cancer,2014
4. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.;Hato;Immunotherapy,2016
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study;Frontiers in Oncology;2022-08-02
2. Immunotherapy in older patients with hepatocellular carcinoma;European Journal of Cancer;2022-02
3. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study;BMC Cancer;2022-01-11
4. Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review;Journal of International Medical Research;2021-09
5. Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patients;Medicine;2021-04-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3